Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation

Movement Disorders

Volumn 29, Issue 4, 2014, Pages 566-568

  Sharp, Madeleine E ^a   Marder, Karen S ^a,b,c   Côté, Lucien ^a,c   Clark, Lorraine N ^a   Nichols, William C ^d   Vonsattel, Jean Paul ^a,c   Alcalay, Roy N ^a,c  

^a Department of Neurology Columbia University ^*  (United States)

^b Vagelos College of Physicians and Surgeons   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Lewy bodies; Neuropathology; Parkin; Parkinson's disease

Indexed keywords

LEVODOPA; PARKIN; PRAMIPEXOLE; QUETIAPINE; SELEGILINE; TRIHEXYPHENIDYL; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DOSE RESPONSE; EXECUTIVE FUNCTION; EXON; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HALLUCINATION; HAND TREMOR; HETEROZYGOSITY; HUMAN; LOCUS CERULEUS; MALE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; GENE DOSAGE; GENETICS; LEWY BODY; MUTATION; PATHOLOGY;

ADULT; GENE DOSAGE; HUMANS; LEVODOPA; LEWY BODIES; MALE; MUTATION; PARKINSON DISEASE; SUBSTANTIA NIGRA; UBIQUITIN-PROTEIN LIGASES;

EID: 84898057599     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25792     Document Type: Article

References (15)

1. Pankratz N, Kissell DK, Pauciulo MW, et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009;73:279-286.
2. Marder K, Tang M-X, Mejia-Santana H, et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol 2010;67:731-738.
3. Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-376.
4. Alcalay RN, Siderowf A, Ottman R, et al. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology 2011;76:319-326.
5. Ruffmann C, Zini M, Goldwurm S, et al. Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2). Acta Neuropathol (Berl) 2012;123:901-903.
6. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive and Motor Function in Long-Duration PARKIN-Associated Parkinson Disease. JAMA Neurology 2013.
7. Clark LN, Haamer E, Mejia-Santana H, et al. Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Mov Disord 2007;22:932-937.
8. Bethlem J, den Hartog Jager WA. The incidence and characteristics of Lewy bodies in idiopathic paralysis agitans (Parkinson's disease). J Neurol Neurosurg Psychiatry 1960;23:74-80.
9. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012;27:831-842.
10. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300.
11. Doherty KM, Silveira-Moriyama L, Parkkinen L, et al. Parkin Disease: A Clinicopathologic Entity? JAMA Neurology 2013:1-9.
12. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005;58:411-422.
13. Doherty KM, Hardy J. Parkin disease and the Lewy body conundrum. Mov Disord 2013;28:702-704.
14. Caccappolo E, Alcalay RN, Mejia-Santana H, et al. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: the CORE-PD Study. J Int Neuropsychol Soc 2011;17:91-100.
15. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.